Medtech Companies Focus on Streamlining Site Collaboration and Data Quality Enhancement

Enhancing Clinical Trials: Medtech's Recent Focus

In an evolving landscape, Medtech companies are increasingly prioritizing collaboration with testing centers and the optimization of data quality. According to findings from the Veeva MedTech Clinical Benchmark 2025, released by Veeva Systems, nearly 70% of surveyed clinical teams recognize the reduction of manual processes as a critical initiative when working with clinical sites. The shift aims to enhance study quality, transparency, and operational efficiency in clinical trials.

Challenges in Site Management

The report underscores that the main challenges include timely data entry, ensuring data quality, and robust documentation exchange among stakeholders. Despite this awareness, only a small percentage of Medtech firms, specifically 14% of those earning over $1 billion, have implemented tools designed to facilitate collaboration with testing sites. This highlights a significant gap as the industry strives to boost study efficiency and streamline timelines.

Statistically, 68% of respondents indicated a preference for decreasing manual interventions, while 56% prioritized improving study quality and over half sought greater transparency in their processes. These statistics illustrate a growing momentum towards leveraging technology to improve clinical workflows. As teams adapt to modern practices, the integration of advanced tools is crucial for uplifting data standardization and streamlining interactions with various testing facilities.

Risks Tied to Manual Processes

The reliance on manual methods remains a pressing concern, with 32% of respondents citing it as a significant hurdle for clinical Medtech organizations. Adherence to international study regulations (18%) and readiness for inspections (18%) were also considered critical barriers. Such challenges could inflate operational costs and lead to postponed timelines for clinical trials, impeding the arrival of innovations to market.

Ongoing Process Improvements

One key finding revealed that 58% of Medtech companies are planning to prioritize data collection and cleansing measures in the upcoming year. By streamlining these processes, organizations anticipate spending less time reconciling data, which would allocate more effort to high-value study activities. This forward-thinking approach is essential for maintaining the integrity of clinical studies.

Investing in Artificial Intelligence

Furthermore, the report found that almost 72% of Medtech organizations are gearing towards investing in Artificial Intelligence (AI) and Machine Learning (ML) solutions. The aim is to harmonize existing systems and standardize data to enable AI readiness. This investment signals a transformative shift in how data is utilized, with potential ramifications for speeding up clinical trial phases.

Kevin Liang, Vice President of Clinical Strategy at Veeva MedTech, articulated, "The Medtech industry is advancing initiatives to improve clinical processes, collaboration with testing centers, and data quality despite economic pressures and new regulations." The emphasis on data integrity further highlights the industry's commitment to enhancing operational efficiency and promoting connected processes across the board.

Insights from the Benchmark Report

The comprehensive nature of the Veeva MedTech Clinical Benchmark 2025 reflects the perspectives of over a hundred clinical professionals from both Medtech and diagnostics firms. The insights garnered from this report foster a deeper understanding of contemporary clinical trials and how teams are progressively modernizing their operations.

Conclusion

For those keen on enhancing their approach to clinical trials, this benchmark underscores the importance of prioritizing cooperation with testing sites and emphasizing quality data management to drive effectiveness in Medtech operations. As the industry grapples with various challenges, harnessing technology will be critical for accelerating the introduction of new therapeutics to patients. To explore further insights, read the full report available through Veeva Systems.